



Resource impact template

Resource impact

Published: 18 October 2023

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for axial spondyloarthritis:

- [Tofacitinib for treating active ankylosing spondylitis](#) (2023) NICE technology appraisal guidance 920
- [Bimekizumab for treating axial spondyloarthritis](#) (2023) NICE technology appraisal guidance 918
- [Upadacitinib for treating active non-radiographic axial spondyloarthritis](#) (2023) NICE technology appraisal guidance 861
- [Upadacitinib for treating active ankylosing spondylitis](#) (2022) NICE technology appraisal guidance 829
- [Secukinumab for treating non-radiographic axial spondyloarthritis](#) (2021) NICE technology appraisal guidance 719
- [Ixekizumab for treating axial spondyloarthritis](#) (2021) NICE technology appraisal guidance 718